Skip to content

Contract Liabilities at other companies

10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$10.14M-19.3%
Danaher logo
DanaherDHR
Agilent Technologies logo
Agilent TechnologiesA
Illumina logo
IlluminaILMN

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Cash & equivalents$124.9M-41.4%
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$5.45B+24.4%
Enterprise value$5.44B+30.4%
P/S13.3×+0.7×

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Twist Bioscience Corporation's contract liabilities?
Twist Bioscience Corporation (TWST) reported contract liabilities of $7.1M in Q1 2026.
How has Twist Bioscience Corporation's contract liabilities changed year-over-year?
Twist Bioscience Corporation's contract liabilities increased by 256.9% year-over-year, from $1.99M to $7.1M.
What is the long-term trend for Twist Bioscience Corporation's contract liabilities?
Over 3 years (2022 to 2025), Twist Bioscience Corporation's contract liabilities has grown at a 25.3% compound annual growth rate (CAGR), from $3.5M to $6.88M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.